<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751386</url>
  </required_header>
  <id_info>
    <org_study_id>130040</org_study_id>
    <secondary_id>13-AA-0040</secondary_id>
    <nct_id>NCT01751386</nct_id>
  </id_info>
  <brief_title>Baclofen for Treating Anxiety and Alcoholism</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Baclofen is a drug used to control muscle stiffness in people with neurological diseases.&#xD;
      Some studies suggest that baclofen may reduce alcohol craving and use. It helps to reduce&#xD;
      anxiety in alcoholics, which in turn can help to reduce cravings. Researchers want to see if&#xD;
      baclofen can be a safe and effective treatment for alcoholics who have high anxiety levels.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To see if baclofen is safe and helpful for people who have alcoholism and high anxiety&#xD;
      levels.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Individuals between 21 and 65 years of age who have been diagnosed with alcoholism and&#xD;
           anxiety issues.&#xD;
&#xD;
        -  Participants must not be taking anti-anxiety medication.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. Blood and urine&#xD;
           samples will be collected. Tests of alcohol dependency and anxiety levels will also be&#xD;
           given.&#xD;
&#xD;
        -  Participants will be divided into two groups. One group will take baclofen. The other&#xD;
           group will have a placebo.&#xD;
&#xD;
        -  About 1 week after the screening visit, participants will have a study visit. They will&#xD;
           answer questions about their behavior and mood. They will then start to take either&#xD;
           baclofen or a placebo. Participants will take the study drug three times a day, every&#xD;
           day.&#xD;
&#xD;
        -  After 1 week on the study drug, participants will have an overnight stay at the National&#xD;
           Institutes of Health. They will have blood tests and answer questions about mood and&#xD;
           behavior. They will also have tests that involve choosing to drink alcohol and answering&#xD;
           more questions about cravings.&#xD;
&#xD;
        -  Participants will stop taking their study drug over a 3-day period.&#xD;
&#xD;
        -  A final follow-up visit will be required 1 week after the overnight study visit.&#xD;
           Participants will receive information about other alcohol abuse treatment programs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      The selective GABAB receptor agonist baclofen has been identified as a possible medication&#xD;
      able to reduce alcohol craving and intake in alcohol dependent individuals. In keeping with&#xD;
      several preclinical studies, most of the clinical studies have demonstrated baclofen s&#xD;
      effects in reducing alcohol craving and intake and promoting alcohol abstinence. However, one&#xD;
      trial with alcoholics with a low severity of dependence found a robust treatment effect, but&#xD;
      no differences between baclofen and placebo. The inconsistency of baclofen s effects on&#xD;
      alcohol drinking among previous treatment trials suggests that different AD individuals may&#xD;
      respond differently to baclofen. Baclofen has been demonstrated to consistently reduce&#xD;
      anxiety in alcoholic patients, and analyses of positive vs. null findings with baclofen&#xD;
      suggest that alcoholic patients with higher levels of anxiety at baseline may represent a&#xD;
      sub-population particularly responsive to baclofen treatment. Therefore, this study will&#xD;
      systematically test, for the first time, the specific role of baclofen on alcohol-related&#xD;
      outcomes in alcoholic individuals with high anxiety levels. Furthermore, the biobehavioral&#xD;
      mechanisms by which baclofen reduces drinking are not well characterized. A human laboratory&#xD;
      pilot study conducted at Brown University with non-treatment seeking alcohol-dependent&#xD;
      individuals suggests that baclofen reduces alcohol consumption both in the naturalistic&#xD;
      environment as well as in a well-controlled lab setting (using an alcohol self-administration&#xD;
      [ASA] paradigm) and that this could be mediated by baclofen s ability to alter&#xD;
      alcohol-related biphasic effects. An exploratory analysis also revealed that specific genetic&#xD;
      polymorphisms might moderate baclofen s effects, i.e. DRD4 and 5HTTLPR polymorphisms,&#xD;
      although the sample of that pilot study was very small to allow one to draft definitive&#xD;
      conclusions. The present project proposes investigating baclofen using a design similar to&#xD;
      that used in the previous pilot study (thus, an already validated paradigm), thus&#xD;
      representing not only the first study testing baclofen in alcoholic individuals with high&#xD;
      anxiety levels, but also the first study investigating baclofen s biobehavioral mechanisms in&#xD;
      such a population for which baclofen may hypothetically show a very robust effect.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Non-treatment seeking alcohol-dependent males and females with high anxiety levels.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      The experimental design is a between-subject randomized double-blind controlled study. The&#xD;
      medication conditions baclofen t.i.d. or placebo represent the between subjects factor. Each&#xD;
      participant will be randomly assigned to one of the two medication conditions and will&#xD;
      receive eight days of the medication, followed by an alcohol laboratory session on Day 8. The&#xD;
      alcohol laboratory session will be conducted in a bar-like room in the NIAAA Outpatient&#xD;
      Clinic of the NIH CRC. The study will be conducted in consecutive phases which will appear&#xD;
      contiguous to volunteers: (1) a one-week screening period; (2) an 8-day period (+ 1-5 days if&#xD;
      needed to permit some participants flexibility in scheduling the laboratory session) during&#xD;
      which participants will take the study medication; (3) an alcohol laboratory session,&#xD;
      including a cue reactivity (CR) test and an alcohol self-administration (ASA) procedure on&#xD;
      Day 8 (last day at the target dose); (4) a 3-day period during which participants will&#xD;
      undergo a dose reduction of the study medication; (5) a 1-week follow-up (including the&#xD;
      tapering phase).&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      Alcohol drinking during the ASA will be measured as the primary outcome. Secondary objectives&#xD;
      include baclofen s effects on alcohol cue-induced responses (urge to drink, attention to&#xD;
      cues, blood pressure, heart rate, saliva), on the subjective effects of alcohol and on&#xD;
      anxiety levels. We will also explore the role of possible moderators of baclofen s effects,&#xD;
      namely family history of alcoholism, early vs. later onset of alcoholism, pre-treatment&#xD;
      anxiety levels and genetic moderators (DRD4, 5-HTTPRL). This study does not offer direct&#xD;
      benefit to participants but is likely to yield generalizable knowledge about the possible&#xD;
      role of baclofen in treating alcoholic individuals with high anxiety levels. This will&#xD;
      markedly facilitate the identification of a novel pharmacotherapy, thus facilitating the&#xD;
      development of novel alcoholism treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 3, 2012</start_date>
  <completion_date type="Actual">August 17, 2016</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</measure>
    <time_frame>2 hours</time_frame>
    <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Dependence</condition>
  <condition>Alcohol Drinking Related Problems</condition>
  <condition>Alcohol Drinking</condition>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen 10 mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <arm_group_label>Baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Must be male or female between 21 and 65 years old (inclusive).&#xD;
&#xD;
          -  Participants must meet criteria for current DSM-IV-TR diagnosis of alcohol dependence,&#xD;
             supported by the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID).&#xD;
&#xD;
          -  Participants must have a Trait STAI &gt; 39.&#xD;
&#xD;
          -  Participants must be in good health as confirmed by medical history, physical&#xD;
             examination, ECG, blood/urine lab tests.&#xD;
&#xD;
          -  Females must be postmenopausal for at least one year, surgically sterile, or&#xD;
             practicing an effective method of birth control before entry and throughout the study;&#xD;
             have a negative urine pregnancy test at each visit. Reliable methods of birth control&#xD;
             include oral contraceptives or Norplant ; barrier methods such as diaphragms with&#xD;
             contraceptive jelly, cervical caps with contraceptive jelly, condoms with&#xD;
             contraceptive foam, or intrauterine devices; a partner with a vasectomy; or abstinence&#xD;
             from intercourse.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Individuals expressing interest in treatment for alcoholism and/or anxiety.&#xD;
&#xD;
          -  Pregnancy or breast feeding women or not using an adequate form of birth control&#xD;
&#xD;
          -  Unable to provide a negative urine drug screen.&#xD;
&#xD;
          -  Individuals diagnosed with a current substance dependence diagnosis, other than&#xD;
             alcohol or nicotine.&#xD;
&#xD;
          -  Meet DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar&#xD;
             disorder, or other psychoses.&#xD;
&#xD;
          -  An active illness within the past 6 months of Visit 1 that meet the DSM-IV criteria&#xD;
             for a diagnosis of Major Depressive Disorder (MDD). Subjects with a history of&#xD;
             attempted suicide will be excluded.&#xD;
&#xD;
          -  Clinically significant medical abnormalities (i.e., unstable hypertension, clinically&#xD;
             significant ECG abnormalities, Creatinine greater than or equal to 2 mg/dL). Although&#xD;
             baclofen has demonstrated a safe profile when administered to alcoholic individuals&#xD;
             with liver cirrhosis, including those with Hepatitis C, this study employs the oral&#xD;
             administration of alcohol. Therefore, individuals with clinically significant liver&#xD;
             problems will be excluded, i.e. liver cirrhosis, AST or ALT &gt; 5 times the upper normal&#xD;
             limit (UNL), and individuals with Hepatitis B and C.&#xD;
&#xD;
          -  Current use of psychotropic medications that cannot be discontinued and that may have&#xD;
             an effect on alcohol consumption (thus confounding the results of the study) or that&#xD;
             may interact with baclofen. Specifically, contraindicated medications will include:&#xD;
             naltrexone, acamprosate, alcohol dehydrogenase inhibitors, topiramate, gabapentin,&#xD;
             ondansetron, benzodiazepines, beta-blockers, H2-blockers, and alpha-1 blockers.&#xD;
&#xD;
          -  Medical contraindications for use of baclofen.&#xD;
&#xD;
          -  A history of adverse reaction or hypersensitivity to baclofen.&#xD;
&#xD;
          -  Participants who have significant alcohol withdrawal symptoms, defined as a CIWA-Ar &gt;&#xD;
             8.&#xD;
&#xD;
          -  History of epilepsy or alcohol-related seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Leggio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-AA-0040.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Addolorato G, Abenavoli L, Leggio L, Gasbarrini G. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology. 2005;51(2):59-66. Epub 2005 Feb 28. Review.</citation>
    <PMID>15741745</PMID>
  </reference>
  <reference>
    <citation>Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002 Sep-Oct;37(5):504-8.</citation>
    <PMID>12217947</PMID>
  </reference>
  <reference>
    <citation>Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002 Feb 15;112(3):226-9.</citation>
    <PMID>11893350</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology (Berl). 2015 Jan;232(1):233-43. doi: 10.1007/s00213-014-3652-9. Epub 2014 Jun 29. Erratum in: Psychopharmacology (Berl). 2015 May;232(9):1667.</citation>
    <PMID>24973894</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, Addolorato G, Swift RM, Kenna GA. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav. 2013 Feb;103(4):784-91. doi: 10.1016/j.pbb.2012.11.013. Epub 2012 Dec 19.</citation>
    <PMID>23262301</PMID>
  </reference>
  <reference>
    <citation>Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, Addolorato G. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012 Apr;37(4):561-4. doi: 10.1016/j.addbeh.2011.12.010. Epub 2011 Dec 27.</citation>
    <PMID>22244707</PMID>
  </reference>
  <results_reference>
    <citation>Farokhnia M, Schwandt ML, Lee MR, Bollinger JW, Farinelli LA, Amodio JP, Sewell L, Lionetti TA, Spero DE, Leggio L. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry. 2017 Apr 25;7(4):e1108. doi: 10.1038/tp.2017.71.</citation>
    <PMID>28440812</PMID>
  </results_reference>
  <verification_date>July 17, 2017</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>July 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2017</results_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>Cue-Induced Craving</keyword>
  <keyword>Craving</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Alcohol Consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NIH Biomedical Translational Research Information System</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</title>
        <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
        <time_frame>2 hours</time_frame>
        <population>The analysis included all subjects who took the medication (either baclofen or placebo) and finished the alcohol laboratory session</population>
        <group_list>
          <group group_id="O1">
            <title>Baclofen</title>
            <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Alcohol Consumed During the Alcohol Self Administration (ASA) Session</title>
          <description>Amount of alcohol was measured as the number of mini-drinks each participant decided to drink (0-8 mini-drinks). The alcohol content of each mini-drink was calculated based on the participants' total body water, and was designed to raise the blood alcohol concentration by 0.015 g/dL.</description>
          <population>The analysis included all subjects who took the medication (either baclofen or placebo) and finished the alcohol laboratory session</population>
          <units>mini-drinks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="0.66"/>
                    <measurement group_id="O2" value="4.5" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baclofen</title>
          <description>Baclofen capsules: 15 mg/day (5 mg t.i.d.; titration phase) for 3 days, followed by 30 mg/day (10 mg t.i.d.; target dose) until the alcohol laboratory session; then, 15 mg/day (5 mg t.i.d.; taper down) for three additional days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsules, similar to baclofen in appearance, texture, taste, and odor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lorenzo Leggio</name_or_title>
      <organization>National Institute on Alcohol Abuse and Alcoholism</organization>
      <phone>+1 301 435 9398</phone>
      <email>lorenzo.leggio@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

